The development of an anti-HIV microbicide is critical in the fight against the 22 spread of HIV. It is shown here that covalently linking compounds that bind gp120 with 23 those that bind gp41 can inhibit HIV entry even more potently than individual inhibitors 24 or non-covalent combinations. The most striking example involves griffithsin, a potent 25 HIV inhibitor that binds to the surface of HIV gp120. While griffithsin inhibits HIV Env-26 mediated fusion in a CCR5-tropic cell-cell fusion assay with an IC 50 of 1.31 ± 0.87 nM, 27 and the gp41 binding peptide C37 shows an IC 50 of 18.2 ± 7.6 nM, the covalently linked 28 combination of griffithsin with C37 (Griff37) exhibited an IC 50 of 0.15 ± 0.05 nM, 8.7-fold 29 greater than griffithsin alone. Similarly, in CXCR4-tropic cell-cell fusion assays, Griff37 30 is 5.2-fold better than griffithsin alone. In viral assays, both griffithsin and Griff37 inhibit 31 HIV replication at mid-picomolar levels, but the linked compound Griff37 is several-fold 32 more potent than griffithsin alone against both CCR5-and CXCR4-tropic virus strains. 33
Division of AIDS, NIAID, NIH and was a gift to that program from Dr. John C. 212
Kappes, Dr. Xiaoyun Wu and Tranzyme Inc (13, 42, 56, 59) . 213 4) HL2/3 cells that stably expressed HIV-1 Env and Tat from the CXCR4-tropic 214 strain HXB2 were obtained through the NIH AIDS Research and Reference 215 from Dr. Barbara K. Felber and Dr. George N. Pavlakis (8) . The cells were 217 maintained in DMEM supplemented with 10 % FBS and 500 µg/mL G418. 218 5) MAGI-CCR5 cells that stably expressed human CD4 and CCR5, naturally 219 expressed CXCR4, and contain an HIV-1 LTR-β-galactosidase reporter gene 220 construct were maintained in DMEM supplemented with 10% fetal bovine serum, 221 100 U/mL penicillin, 100 µg/mL streptomycin, 300 µg/mL L-glutamine, 0.2 mg/mL 222 G418, 0.1 mg/mL hygromycin B and 1 µg/mL puromycin. These cells were 223
obtained through the NIH AIDS Research and Reference Reagent Program, 224
Division of AIDS, NIAID, NIH and were a gift to that program from Dr. Julie 225
Overbaugh (3). 226
6) 293FT cells were maintained in DMEM supplemented with 10 % FBS and were a 227 kind gift from Dr. Jennifer Manilay, originally obtained from Invitrogen (Carlsbad, 228 CA) . In addition, fresh human PBMCs were isolated and used in antiviral assays as 234 previously described (32, 48) . was used to fit the data into a four-parameter logistic equation. Some combinations of 264 compounds were assessed for possible synergistic effects by calculating the C.I. 265 (Combination Index) (7). P-values were obtained using an unpaired, 2-tailed student's 266 t-Test in Microsoft Excel. Supplemental Tables show more comparisons by this 267
method. 268 269
In the CXCR4-tropic fusion assay, HeLa-TZM-bl cells were used as target cells 270 and HL2/3 cells were used as effector cells. The rest of the procedure was identical to 271 the CCR5-tropic fusion assay. 272
273
In the competition CCR5-tropic fusion assay, 5x10
3 HeLa-P5L cells were seeded 274 together with 5x10 3 3T3 cells per well. The rest of the procedure was identical to the 275 normal CCR5-tropic fusion assay. 276
277
In the low temperature CCR5-tropic fusion assay, the addition of effector cells to 278 target cells was immediately followed by 2 hours of incubation at 16 o C. The plate was 279 returned afterwards to the 37 o C cell incubator for 24 hours. 280
281
In the wash-out assay, HeLa-ADA or HeLa-P5L cells (10 4 cells) were seeded in a 282 96 well plate the day before the assay. After the formation of the inhibitor gradient by 283 serial dilution, as described above, the cells remained at room temperature for 30 min. Transfection System (Promega)). 48 hours post-transfection, the supernatant was 295 harvested, centrifuged at low speed, and filtered with a 0.45 um syringe filter. This viral 296 stock was stored at -80 o C. For the assay, 10 4 TZM-bl cells per well were seeded in a 297 96 well plate. The next day, the media was removed and replaced with 50 µL of new 298 media. Serial dilutions of inhibitor were carried out in the wells of the plate: 20 µL of 299 protein or peptide was added to the first well and mixed, then 20 µL was removed and 300 added to the next well and so on. Virus was added in an amount to obtain a luciferase 301 signal between 60,000-80,000 arbitrary units for the ADA-env pseudo virus (while the 302 control of non-infected cells gave ~600 arbitrary units) and 40,000-60,000 arbitrary units 303 for the JR-FL-env pseudo virus. The total volume of media per well after pseudo virus 304 addition was 100 µL. After 24 hours, old media was removed and replaced with new 305 media. A further 24 hours later, the media was removed and the cells were lysed using 306
Glo lysis Buffer (Promega) according to the manual. Luciferase substrate was then 307 added (Luciferase Assay System (Promega)) and the plate was read using an Orion II 308 microplate luminometer (Berthold Techniques, Germany). For Griff37I642D and 309 on July 8, 2017 by guest http://aac.asm.org/
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Griff37-shortlink, the CPRG substrate was used as described for the cell fusion assay. 310
The percentage of viral infection was calculated as [100 x (mean absorbance of treated 311 well-mean absorbance of TZM-only well)] / (mean absorbance of viral infection in the 312 absence of inhibitor -mean absorbance of TZM-only well). The results were plotted 313 using Microsoft Excel, and the IC 50 and IC 90 were calculated using a linear equation 314 fitted between two experimental points surrounding the IC 50 or IC 90 . 315
316

MAGI antiviral assays 317
The CCR5-and CXCR4-tropic MAGI antiviral assays were both performed using 318 MAGI-CCR5 cells in a manner identical to the CCR5-tropic HIV-1 entry assay described 319 previously (32), with the exception that the virus and test compounds were left in the 320 culture for the entire 48 hour incubation period, compared to washing out of virus and 321 test compound 3 hours post-infection for the HIV-1 entry assay. 322
HIV-1 strains Ba-L and ADA were used for the CCR5-tropic assays, and HIV-1 323 strain IIIB was used for the CXCR4-tropic assays. Co-receptor dependence for each of 324 the viruses used to infect MAGI-CCR5 cells, which express both CCR5 and CXCR4, 325 was verified through the use of AMD3100 (CXCR4 inhibitor; positive control inhibitor for 326 IIIB, and negative control inhibitor for Ba-L and ADA) and TAK779 (CCR5 inhibitor; 327 positive control inhibitor for Ba-L and ADA, and negative control inhibitor for IIIB) as 328 control compounds (data not shown). Data processing was performed in a similar 329 manner as described above for the single round infection assay. In these cell-based 330 assays, cell viability and 50% toxic concentrations (TC 50 s) were derived by using a 331 commercially available soluble tetrazolium-based MTS reagent (CellTiter 96 AQueous 332 on July 8, 2017 by guest http://aac.asm.org/
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One Solution cell proliferation assay), which uses a colorimetric method for determining 333 the number of viable cells in proliferation, cytotoxicity, or chemosensitivity assays). All 334 tested compounds showed no toxicity at the highest tested concentration (100 nM for 335 C37, 10 nM for griffithsin and Griff37) (32). 336
337
NMR spectroscopy 338
Samples that were isotopically labeled with 
368
The results of CCR5-tropic cell-cell fusion assays are shown in Figure 1 and 369 Table 1 . Griffithsin alone performs well, with an IC 50 of 1.31 nM ± 0.87, and the 370 C-peptide C37 has an IC 50 of 18.2 ± 7.5 nM in this assay. The two proteins in 371 combination without being linked inhibit quite well, exhibiting an IC 50 of 0.46 nM (for 372 each protein, for a total concentration of 0.91 nM at 50% inhibition). However, when the 373 griffithsin and C37 are covalently joined by a 16 amino acid linker to form Grft-linker-374 C37 (hereafter referred to as Griff37), the effectiveness of the compound in the fusion 375 assay increases dramatically, giving an IC 50 of 0.15 ± 0.05 nM ( Figure 1A , Table 1) , 376 which is 8.7-fold greater than griffithsin alone. It has been reported that the activity of 377 C-peptides can be enhanced by making the point substitution Q652L (53), so this 378 on July 8, 2017 by guest http://aac.asm.org/ Downloaded from substitution was made in the linked compound. Griff37Q652L was produced and 379 purified, but in the CCR5-tropic fusion assay this compound has approximately the 380 same effectiveness as Griff37 (Table 1) . Conversely, substitution of Asp for Ile at 381 position 642 in C37 has been reported to diminish the activity of C37 (28) so this I642D 382 substitution was made in Griff37, and the resulting protein showed 2.4-fold worse 383 inhibition in the fusion assay than Griff37, but still 2-fold better than griffithsin alone 384 (data not shown). When the linker between griffithsin and C37 was shortened to 4 385 amino acids, the resulting protein was1.6-fold worse than Griff37, but still 3.1-fold better 386 than griffithsin alone (data not shown). 387
388
As a further test of the overall strategy to link gp120 binding molecules with gp41 389 binding molecules, the peptide C37 was linked with a 16 amino acid linker to a modified 390 version of the peptide CD4M33, an HIV inhibitor that was designed to bind gp120 in a 391 manner similar to the protein CD4 (37). While the published peptide contains unnatural 392 amino acids in positions 1 and 23, we replaced these with natural amino acids Cys and 393
Phe respectively in order to allow expression in E. coli. We will refer to this peptide as 394 CD4M33 C1F23 . In CCR5-tropic fusion assays, C37-linker-CD4M33 C1F23 395 (C37CD4M33 C1F23 ) exhibited an IC 50 of 6.84 ± 2.9 nM (Table 1 ). This value is 396 significantly lower than that for either component alone in cell-cell fusion assays, since 397 C37 has an IC 50 of 18.2 nM, and His-tag-containing CD4M33 C1F23 was not an effective 398
inhibitor even at our highest tested amount of 1.4 µM (data not shown). Synthetically 399 produced CD4M33 (37) had an IC 50 higher than 1000 nM in our hands in this fusion 400 assay (Table 1) . We also produced the compound Griffithsin-linker-CD4M33 C1F23 401 on July 8, 2017 by guest http://aac.asm.org/ Downloaded from (GriffCD4M33 C1F23 ), which could provide two molecules that bind to gp120. This 402 compound performed reasonably well in CCR5-tropic cell-cell fusion assays, with an 403 IC 50 of 3.47 ± 0.97 nM, but did not appear to have enhanced activity compared to the 404 individual components of the molecule. 405
These results suggest the possibility that combining a gp120 binding protein 406 (such as Griffithsin or CD4M33) with a gp41 binding protein (such as C37) is a potent 407 strategy for inhibition of CCR5-tropic HIV. 408
409
Strategically linked compounds are potent in CXCR4-tropic cell-cell fusion assays. 410
The linked combination of griffithsin and C37 was also quite potent in CXCR4-411 tropic cell-cell fusion assays. As shown in Figure 1 and Table 1 , while griffithsin alone 412 exhibited an IC 50 of 0.47 ± 0.27 nM, the linked Griff37 was 5.3-fold more potent, similar 413 to the point mutant of the linked compound, Griff37Q652L (Table 1) . When unlinked, 414 the combination of griffithsin and C37 were only slightly more potent than each 415 separately ( Figure 1B and Table 1) . 416
When C37 was linked with the gp120-binding peptide CD4M33 C1F23 , the 417 resulting C37CD4M33 C1F23 gave an IC 50 of 2.30 ± 0.98 nM. Since this is close to the 418 value of C37 alone, and CD4M33 has been shown to inhibit in a CXCR4-tropic fusion 419 assay in the micromolar range (IC 50 of 0.8 ± 0.09 µM) (38), it appears that linking the 420 two inhibitors in this case does not improve inhibition. Interestingly, these results differ 421 from the CCR5-tropic cell-cell fusion assay, where the C37CD4M33 C1F23 compound 422 gave an IC 50 that was better than either compound alone (Table 1) . 423
Strategically linked compounds perform well in viral and pseudoviral assays. 425
To confirm that the strategy of linking a gp120-binding protein with a gp41-426 binding peptide is successful in inhibiting HIV replication, a series of assays were 427 performed using several types of target cells and viral strains. In replication competent 428 HIV assays, the linked compound Griff37 consistently performs better than griffithsin 429 alone. For example, when the CCR5-tropic HIV-1 strain Ba-L is used to infect MAGI 430 cells, griffithsin alone exhibits an IC 50 of 0.04 ± 0.01 nM, while Griff37 is 2.7-fold better, 431
with an IC 50 of 0.015 ± 0.005 nM (Table 2, Figure 2 ) and the unlinked combination of 432 griffithsin and C37 has an IC 50 of 0.05 nM in each protein. Similarly, when the CCR5-433 tropic HIV-1 strain ADA infects MAGI cells, Griff37 is 2-fold better than griffithsin alone 434 and 6.3-fold better than the unlinked combination of griffithsin and C37 (total protein 435 concentration) ( Table 2 ). The effect in most cases is even more dramatic when 436 comparing concentration at 90% inhibition (IC 90 ) for these compounds against viral 437 strains: For Ba-L, Griff37 is 6.4-fold more potent than Griffithsin and 9.4-fold more 438 effective than the unlinked combination (Table 2) ; similar results are observed for 439 inhibition of strain ADA. 440
As described for fusion assays, these compounds are also highly effective 441 against CXCR4-tropic HIV strains. When MAGI cells are infected by the CXCR4-tropic 442 strain HIV-1 IIIB, Griff37 again shows several-fold higher potency than its components 443 (Table 2) . 444
Similar results are observed when human PBMCs are infected with HIV-1 Ba-L. 445
In this case, griffithsin alone has an IC 50 of 0.28 ± 0.17 nM, while Griff37 is 4.7-fold 446 better, with an IC 50 of 0.059 ± 0.0004 nM, and the unlinked components griffithsin plus 447 on July 8, 2017 by guest http://aac.asm.org/ Downloaded from C37 are less than two-fold better than griffithsin alone (Table 3) . When the CCR5-tropic 448 HIV-1 clinical isolate 91US005 is used to infect PBMCs, the result is about a two-fold 449 improvement for Griff37 over griffithsin alone (Table 3) . GriffC37 also shows a 3.8-fold 450 increase in anti-HIV potency compared to Griffithsin alone in CXCR4-tropic strains NL4-451 3 and 92HT599 (primary strain; Table 3 ). Since the griffithsin-containing compounds 452
were clearly more potent than the CD4M33 C1F23 -containing compounds, the 453 CD4M33 C1F23 compounds were not tested in replication competent viral assays. 454
455
In single-round infection assays griffithsin and its analogs all perform quite well. 456
HIV virions pseudotyped with Env from the CCR5-tropic HIV-1 strains JR-FL or ADA 457 were both used in inhibition assays. While Griff37 performed marginally better in IC 50 458 than griffithsin alone with strain JR-FL, it did not perform better using strain ADA ( Table  459 4). Indeed, using strain ADA in a single round infection assay was the only instance we 460 identified in which Griff37 was not superior to griffithsin (Tables 1, 2 , 3, 4). Mutation to 461 disrupt the activity of the C37 component of Griff37 (Griff37I642D) showed a loss of 462 activity in the JR-FL strain, while mutation to shorten the linker (Griff37-shortlink) 463 resulted in a protein that was still quite potent, with an activity close to that of Griff37 464 (Table 4 ). In addition, the combination of gp41 binding peptide C37 with gp120-binding 465 CD4M33 C1F23 , C37CD4M33 C1F23 , also appears to perform moderately better in CCR5-466 tropic pseudoviral assays than the components C37 alone (~13 fold); or recombinant 467 CD4M33 C1F23 (not active); or synthetic CD4M33, which Martin et. al showed to have 468 nanomolar inhibition in other strains, although in our hands the inhibition of CD4M33 469 alone was less effective (Table 4 and (38) For a potential therapeutic to be beneficial in an organism, it needs to be able to 477 effectively find its target in the milieu of other cell types and potential binding partners. 478
As a test of this ability, the CCR5-tropic cell-cell fusion assay was modified with the 479 addition of fibroblast mouse 3T3 cells which serve as a connective tissue surrogate 480 supplying proteins and carbohydrates. These cells are not able to be infected by HIV 481 and do not have human coreceptors on their surface, but they present a myriad of 482 proteins and carbohydrates that could potentially bind an anti-HIV therapeutic and 483 confound its ability to inhibit in the assay. 484
485
As we previously reported, in a CCR5-tropic fusion assay in the presence of 486 unrelated competitor cells, the peptide C37 performs significantly worse than in the 487 absence of such cells, with an IC 50 of 61.4 ± 7.9 nM ((27) and Table 1 ). This leads to 488 the possibility that Griff37 also performs worse in the presence of unrelated cells due to 489 the presence of C37. However, the linked compounds perform quite well under these 490 conditions. The presence of competitor cells does not greatly affect griffithsin-491 containing compounds, as griffithsin alone still performs well. But Griff37 again 492 performs significantly better than griffithsin alone (Table 1) . When C37 is linked to 493 on July 8, 2017 by guest http://aac.asm.org/ Downloaded from gp120-binding peptide CD4M33 to make C37CD4M33 C1F23 , the resulting IC 50 is 7.78 ± 494 1.6 nM, which is close to the value in the absence of competition. Similar results were 495 also observed for Griff37 in single round infection assays using virus pseudotyped with 496
Env from the CCR5-tropic HIV-1 strain JR-FL in the presence of competitor cells. In 497 these experiments, all griffithsin-containing assays performed well, but Griff37 498 performed better than griffithsin alone (data not shown). 499
500
To determine whether the linked inhibitors maintain some of their activity under 501 conditions of washing out, modified R5 fusion assays were carried out. In these assays, 502 either the target cells or effector cells were placed in a well in the presence of inhibitor. 503
The supernatant was then removed, cells were washed twice with PBS, and inhibitor-504 free media added, followed by the addition of the other cell type to allow fusion to 505 proceed. Therefore, inhibition would only be observed for inhibitors that can maintain 506 their presence rather than be washed away. In these assays, an IC 50 for C37 could not 507 be determined because it was apparently fully washed out. However, both griffithsin 508 and Griff37 maintained nanomolar effectiveness when first bound to the ADA "HIV 509 effector cells" before the washing step. It is worth mentioning that when the inhibitors 510 were incubated with the target cell before the washing step vigorous washing were 511 needed to wash away griffithsin and Griff37, indicating a low level of nonspecific binding 512 of griffithsin to the cell surface (data not shown). This low level of nonspecific binding 513 does not affect the anti-HIV potency of griffithsin as indicated by both competition assay 514 (Table 1) 
NMR experiments on the anti-HIV compounds 522
Nuclear magnetic resonance (NMR) is a very effective technique for determining 523 structural details of proteins, including their extent of foldedness and the possibilities for 524 their oligomeric state (9, 17, 34) . Figure 3A Figure 3B shows the spectrum of the linked compound Griff37. Despite this 533 protein exhibiting potent anti-HIV activity in numerous assays, the spectrum shows 534 strong signal around 8.2 ppm in the 1 H dimension, indicative of unfolded or random coil 535 protein in the sample. There are also peaks (of lower intensity) in the "folded" region of 536 the spectrum (particularly above 9 ppm), and an overlay of this spectrum with griffithsin 537 alone indicates that these peaks arise from folded griffithsin (overlay not shown). NMR experiments were also carried out on the C37CD4M33 C1F23 peptide 540 combination. Since this compound is a fusion of two peptides (albeit functionally active 541 peptides), the unfolded peaks that are observed in the 8.2 ppm region of Figure 3c were 542 expected. However, there were also peaks indicative of folded protein (several circled 543 in Figure 3C ). Since C34 (nearly identical to C37) has been shown to be unfolded in the 544 absence of its gp41 binding partner (36), it is likely that the peaks in this region of the 545 spectrum result from folded CD4M33 C1F23 . The parent compound, CD4M33, was 546 designed by Martin et al. to be a folded peptide containing unnatural amino acids and 547 was produced for their work by chemical synthesis (38) . Therefore, it is notable that 548 although we made multiple changes to CD4M33, including the use of "natural" amino 549 acids to replace the designed unnatural amino acids, the use of recombinant expression 550 rather than synthesis, and linkage with another peptide, the resulting protein still is an 551 active anti-HIV compound that is at least partly folded. characteristics. In addition to remarkably high potency, it is stable upon incubation at 37 568 °C, which is a necessary property if it must remain active in the human body for hours or 569 be stored without refrigeration (16). It also retains its activity in cervical/vaginal lavage 570
fluid (16), is non-inflammatory in human cervical explants, is non irritating in a rabbit 571 vaginal model and is active against multiple clades of HIV, indicating likely usefulness in 572 many or all of the areas hardest hit by this disease (41). 573
574
The most effective inhibitor in our experiments was Griff37, or possibly its slight 575 variant Griff37Q652L, both compounds that covalently link griffithsin with the C-peptide 576 C37. This linked inhibitor performed at sub-nanomolar levels in both CCR5-and 577 CXCR4-tropic fusion assays, and at mid-picomolar levels in viral assays. These values 578 are in almost every case better than for griffithsin alone and better than an unlinked 579 combination of griffithsin and C37 (Tables 1, 2 In the replication competent viral assays, the improvement in the IC 90 for the 587 linked compound Griff37 was more statistically significant than the IC 50 which is a 588 positive indicator since 90% inhibition is perhaps more critical for truly stopping 589 infection. Statistical significance is judged by a comparison of the p-values derived from 590 the student's t-Test as described in Methods. The Supplemental tables also contain p-591 values for a comparison of the linked compounds with their unlinked controls for many 592 types of assay presented here. The greater effectiveness of Griff37 at the higher 593 concentrations needed for 90% inhibition in the viral assay could be partly explained by 594 the increasing importance of the C37 component at these concentrations because C37 595 inhibits at nanomolar levels. As the concentration of the inhibitor rises from picomolar 596 levels (where griffithsin functions, based on its IC 50 ), to nanomolar levels, the C-peptide 597 may contribute more to the overall inhibition. As a further test of the strategy of 598 covalently linking a gp120-binding compound with a gp41-binding compound, the linked 599 peptide C37CD4M33 C1F23 was produced. Again, this compound consistently showed 600 more potent inhibition than either component separately in the CCR5-tropic cell-cell 601 fusion assay (Tables 1 and 4) . 602
603
In deriving a set of possible models for the explanation of the effectiveness of 604 Griff37, each model must account for the fact that this linked molecule is a significantly 605 better inhibitor than the unlinked combination of the two components. In keeping with 606 this observation, there are at least three plausible models for the mechanism of action 607 of Griff37. The first model is that the griffithsin moiety binds to gp120 with high affinity, 608 and the role of the linked C37 is simply to provide a more sizeable protein on gp120 609 (Figure 4A) , making a more effective blockade against binding to CD4 or CCR5. 610
However, arguing against this simple steric mechanism is the evidence that griffithsin 611 linked to the peptide CD4M33 (GriffCD4M33 C1F23 ) also would be expected to be able to 612 provide a similar binding blockade, and yet this molecule does not show enhanced 613 inhibition compared to griffithsin alone. Also, Griff37I642D, which carries a substitution 614 that negatively affects C37 binding to gp41, shows decreased activity. This indicates 615 that C37 function is important to the activity of the linked compound. A second model is 616 one in which the griffithsin component binds to gp120, thereby delivering C37 close to 617 its binding site on gp41. By being in physical proximity to gp41, C37 is able to bind 618 gp41 and inhibit fusion if and when gp41 is exposed, possibly dislodging the linked 619 griffithsin at that time. In this scenario, it is assumed that only one component of the 620 linked pair is binding to its site at any given time, although they may both be in an on-off 621 equilibrium with their respective binding sites ( Figure 4B ). Note that griffithsin is a tight 622 dimer (62, 63), so Griff37 likely brings two molecules of C37 to a single viral spike, 623 although for simplicity the dimer structure is not shown in Figure 4 . 624
625
In the third model of action for Griff37, both components (i.e. griffithsin and C37) 626 are bound to their respective targets simultaneously. The 16 amino acid linker used in 627
Griff37 was designed to be flexible and to allow simultaneous binding of the two 628 In order to address whether the model presented in Figure 4B or 4C is more 636 correct, a shortened linker was constructed for Griff37, called Griff37-shortlink. We 637 reasoned that if both griffithsin and C37 bound simultaneously to their targets (as in 638 Figure 4C ), a shortened linker would have significantly reduced activity (down to the 639 level of griffithsin), since this length is likely not sufficient for simultaneous binding. We 640 found that in cell fusion assays, Grif37-shortlink did inhibit less well than Griff37, 641
indicating that linker length is important in this type of assay. In contrast, Griff37-642 shortlink inhibited similarly to Griff37 in single round viral assays (Table 4) . Since a 643 single round infection assay is more representative of a replication-competent viral 644 infection, we believe that the model in Figure 4B , showing non-simultaneous binding of 645 griffithsin and C37, is more likely. Experiments are ongoing in this regard. 646
647
Similarly to the results with Griff37, experiments reported here with linked 648 peptides also indicates the beneficial effects of binding both gp120 and gp41, although 649 E. coli production without optimization leads to the possibility that the effect could be 650 stronger after improved refolding conditions are determined. The compound 651 (25, 26) . This group also produced another excellent compound by linking a CCR5 688
antibody with a C-peptide (30). In both cases, the antibody was expressed having one 689 C-peptide at the C-terminus of each heavy chain of the antibody, resulting in a ratio of 690 2:1 C-peptide: antibody. While both of these chimeric compounds would likely be highly 691 effective microbicides, they have the disadvantage of being produced in a mammalian 692 cell system (HEK cells), which would make it difficult to produce gram-quantities of the 693 inhibitor. In our system, Griff37 was produced from E. coli in shaker flasks and could 694 likely be produced in large quantities by fermentation or in a plant based expression 695 system, both of which were recently shown to be useful in making large quantities of 696 functional griffithsin (22, 41) . Another effective HIV inhibitor was produced by linking 697 two domains from CD4 with a single chain variable region from the antibody 17b, which 698 is known to interact with gp120 on a site near its CCR5-binding region. This inhibitor 699 for the presence of strong peaks in the unfolded region of the spectrum despite the 716 protein being quite active. First, the 16 amino acid linker between griffithsin and C37 717 was designed to be structurally flexible, so the signal from this region is expected to 718 resonate in the "unfolded" region of the spectrum. Second, the peptide C37 is likely 719 unfolded in the absence of a binding partner (35), which would lead to peaks in the 720 unfolded region of the spectrum due to this peptide, even if the peptide would be fully 721 active when presented with a binding partner in an assay. Finally, if the Griff37 protein 722 on July 8, 2017 by guest http://aac.asm.org/ Downloaded from forms oligomers or loose aggregates, line broadening would occur, which would have 723 the effect of decreasing the intensity of all the peaks, particularly those from residues 724 that are not free to move quickly in solution. Therefore, a globular protein like griffithsin 725 would be expected to lose a great deal of signal intensity upon oligomerization. Overall, 726 the spectrum of Griff37 suggests a sample that is at least partially folded (due to the 727 clear presence of peaks that overlap with those in the griffithsin sample) but that may 728 have a percentage of the sample unfolded and/or a portion of the sample in an 729 oligomerized state. In this case, small improvements to the refolding procedure may 730 lead to significantly more potent inhibitors. 731
732
The strategically linked compounds reported here show picomolar levels of 733 activity in many assays, but may still be able to be improved. For example, the 734 C-peptide component may be able to be improved by capping the charged ends that 735 occur naturally when a protein is expressed rather than synthesized (53). In our hands, 736 N-acetylated, C-amidated C37 inhibits in the CCR5-tropic fusion assay with an IC 50 of 737 18.2 nM, as reported above. However, C37 without the terminal modifications inhibits 738 with an IC 50 of >100 nM. Therefore, it is possible that capping the C-terminal end of 739 Griff37 and C37CD4M33 C1F23 could increase the potency of these compounds. In 740 addition, others have reported further improvements in C-peptides that increase their 741 potency (12), which may be able to be incorporated into the strategy presented here. 
